Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-201 in HPV 16+ Oropharynx and Cervical Cancer
NCT04630353Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Oncolytic Viruses, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of HB-201 in oropharyngeal cancer and Cervical Cancer (CC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer. Started Jul 2021; status: terminated.
02
Drugs
HB-201
03
Conditions
oropharyngeal cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT04630353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630353.